Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Orchestra BioMed Holdings, Inc.
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
November 12, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed to Participate in Jefferies London Healthcare Conference
November 07, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 12, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
MDT
OBIO
Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
July 30, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
June 04, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
May 22, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
May 13, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
April 30, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
April 30, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
March 27, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
MDT
OBIO
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
March 26, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
March 13, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
MDT
OBIO
Orchestra BioMed to Participate in Upcoming Investor Conferences
March 07, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
March 06, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
February 26, 2024
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
MDT
OBIO
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
September 19, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
MDT
OBIO
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
August 08, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
June 26, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
June 07, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
MOTS
OBIO
Orchestra BioMed to Present at the Jefferies Global Healthcare Conference
June 01, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed to Present at Upcoming Investor Conferences
March 07, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Orchestra BioMed Strengthens Senior Leadership Team
February 07, 2023
From
Orchestra BioMed Holdings, Inc.
Via
GlobeNewswire
Tickers
OBIO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.